{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:03:50Z","timestamp":1778555030131,"version":"3.51.4"},"reference-count":39,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Iron deficiency and anemia characterize patients on chronic hemodialysis (HD). Available intravenous iron agents, such as ferric gluconate (FG) and ferric carboxymaltose (FCM), vary in dosing regimens and safety profiles. The aim of the present study was to analyze the modification of the iron status, the correction of anemia, and the economic implications after the shift from FG to FCM therapy in chronic HD patients. We evaluated, during the study, the variations in iron metabolism, assessing ferritin and transferrin saturation, erythropoietin-stimulating agent (ESA) doses and the number of administrations, the effects on anemic status, and consequent costs. Materials and Methods: A retrospective study was performed with a follow-up period of 24 months, enrolling forty-two HD patients. The enrolment phase started in January 2015, when patients were treated with iv FG, and continued until December 2015, when FG was discontinued, and, after a wash-out period, the same patients were treated with FCM. Results: The iron switch reduced the administered dose of ESA by 1610.500 UI (31% of reduction; p &lt; 0.001) during the entire study period and reduced the erythropoietin resistance index (ERI) (10.1 \u00b1 0.4 vs. 14.8 \u00b1 0.5; p &lt; 0.0001). The FCM group had the highest percentage of patients who did not require ESA treatment during the study period. The FCM patients were characterized by higher levels of iron (p = 0.04), ferritin (p &lt; 0.001), and TSAT levels (p &lt; 0.001) compared to the FG patients. The annual cost during FG infusion was estimated at EUR 105,390.2, while one year of treatment with FCM had a total cost of EUR 84,180.7 (a difference of EUR 21,209.51 (20%), saving EUR 42.1 per patient\/month (p &lt; 0.0001). Conclusions: FCM was a more effective treatment option than FG, reducing ESA dose requirements, increasing Hb levels, and improving iron status. The reduced ESA doses and the decreased number of patients needing ESA were the main factors for reducing overall costs.<\/jats:p>","DOI":"10.3390\/medicina59061071","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T03:25:54Z","timestamp":1685676354000},"page":"1071","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1705-8770","authenticated-orcid":false,"given":"Antonio","family":"Lacquaniti","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, Papardo Hospital, 98158 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romana","family":"Gargano","sequence":"additional","affiliation":[{"name":"Department of Economics, University of Messina, 98100 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Campo","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Papardo Hospital, 98158 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Casuscelli di Tocco","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Papardo Hospital, 98158 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Schifilliti","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Clinical Pharmacy Fellowship, University of Messina Annunziata Campus, 98168 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0492-5022","authenticated-orcid":false,"given":"Paolo","family":"Monardo","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Papardo Hospital, 98158 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000486968","article-title":"Positive iron balance in chronic kidney disease: How much is too much and how to tell?","volume":"47","author":"Wish","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5414\/CNP57136","article-title":"Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients","volume":"57","author":"Chang","year":"2002","journal-title":"Clin. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Campo, S., Lacquaniti, A., Trombetta, D., Smeriglio, A., and Monardo, P. (2022). Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133759"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.2215\/CJN.00510119","article-title":"Intravenous Iron Use in the Care of Patients with Kidney Disease","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"PIVOTAL Investigators and Committees. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10198-013-0533-9","article-title":"Budget impact of parenteral iron treatment of iron deficiency: Methodological issues raised by using real-life data","volume":"15","author":"Brock","year":"2014","journal-title":"Eur. J. Health Econ."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Diebold, M., and Kistler, A.D. (2019). Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1263-8"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1093\/ndt\/gfq069","article-title":"The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: A multi-centre, open-label, clinical study","volume":"25","author":"Covic","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hofman, J.M.G., Eisenga, M.F., Diepenbroek, A., Nolte, I.M., Van Dam, B., Westerhuis, R., Bakker, S.J.L., Franssen, C.F.M., and Gaillard, C.A.J.M. (2018). Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1045-8"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.23876\/j.krcp.20.015","article-title":"Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up","volume":"39","author":"Lacquaniti","year":"2020","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1007\/s12325-019-01089-z","article-title":"Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy","volume":"36","author":"Rognoni","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rosati, A., Conti, P., Berto, P., Molinaro, S., Baldini, F., Egan, C.G., Panichi, V., and Tuscany Study Group for Ferric Carboxymaltose (2022). Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11185284"},{"key":"ref_14","first-page":"279","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"McMurray","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000493551","article-title":"Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data","volume":"48","author":"Macdougall","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.34067\/KID.0004272021","article-title":"Stroke in He-modialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analy-sis from the PIVOTAL Trial","volume":"2","author":"Mark","year":"2021","journal-title":"Kidney360"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1681\/ASN.2019090972","article-title":"Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial","volume":"31","author":"Macdougall","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/ndt\/gfk011","article-title":"Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients","volume":"21","author":"Locatelli","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","unstructured":"Pesarin, F. (2001). Multivariate Permutation Tests: With Application in \u201cBiostatistics\u201d, John Wiley & Sons."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2215\/CJN.03850321","article-title":"Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial","volume":"16","author":"Bielesz","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1038\/s41598-021-86769-z","article-title":"Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: An observational retrospective study and cost analysis","volume":"11","author":"Cirillo","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cappell, K.A., Shreay, S., Cao, Z., Varker, H.V., Paoli, C.J., and Gitlin, M. (2014). Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels. BMC Nephrol., 15.","DOI":"10.1186\/1471-2369-15-116"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1111\/hdi.12558","article-title":"Safety of intravenous iron in hemodialysis patients","volume":"21","author":"Li","year":"2017","journal-title":"Hemodial. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0272-6386(95)90151-5","article-title":"Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation","volume":"26","author":"Fishbane","year":"1995","journal-title":"Am. J. Kidney Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1681\/ASN.V113530","article-title":"Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients","volume":"11","author":"Besarab","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/ndt\/gfw264","article-title":"Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: An analysis of the 1-year FIND-CKD trial","volume":"32","author":"Roger","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients\u2019 Response to IV Iron with Elevated Ferritin (DRIVE) Study","volume":"18","author":"Coyne","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mikhail, A., Brown, C., Williams, J.A., Mathrani, V., Shrivastava, R., Evans, J., Isaac, H., and Bhandari, S. (2017). Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0688-1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000515639","article-title":"The Relationship between Serum Ferritin Levels and 5-Year All-Cause Mortality in Hemodialysis Patients","volume":"51","author":"Erdem","year":"2022","journal-title":"Blood Purif."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3389\/fimmu.2019.01885","article-title":"Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo","volume":"10","author":"Faria","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.21873\/invivo.12419","article-title":"Intravenous Iron Replacement Therapy Improves Cardiovascular Outcomes in Hemodialysis Patients","volume":"35","author":"Righini","year":"2021","journal-title":"In Vivo"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.ajkd.2011.07.014","article-title":"Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: Results from a cohort study from the dialysis registry in Japan","volume":"59","author":"Fukuma","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.ajkd.2016.01.011","article-title":"Dosing penalty of erythropoiesis-stimulating agents after switching from originator to biosimilar preparations in stable hemodialysis patients","volume":"68","author":"Minutolo","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14740338.2016.1182494","article-title":"An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease","volume":"15","author":"Locatelli","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/ndt\/gfx269","article-title":"Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: A propensity score-matched analysis","volume":"33","author":"Varas","year":"2018","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1071\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:47:33Z","timestamp":1760125653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["medicina59061071"],"URL":"https:\/\/doi.org\/10.3390\/medicina59061071","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}